1. Which of the following statements about dengue fever is true?
a) It is caused by a bacteria
b) It is caused by a virus
c) It is a non-communicable disease
d) It is a childhood disease
2. Which mosquito species is the primary vector for transmitting the dengue virus?
a) Anopheles mosquito
b) Culex mosquito
c) Aedes aegypti mosquito
d) Simulium mosquito
3. How many serotypes of the dengue virus are known to exist?
a) 2
b) 4
c) 6
d) 8
4. Which of the following is NOT a common symptom of dengue fever?
a) High fever
b) Muscle and joint pain
c) Nausea and vomiting
d) Sore throat
5. What is the term used to describe a potentially life-threatening complication of dengue fever?
a) Dengue hemorrhagic fever
b) Malaria
c) Yellow fever
d) Zika fever
6. Which of the following is the first licensed dengue vaccine?
a) Dengvaxia
b) Chikungunya vaccine
c) Zika vaccine
d) Yellow fever vaccine
7. What type of vaccine is Dengvaxia?
a) Inactivated virus vaccine
b) Live attenuated virus vaccine
c) Subunit vaccine
d) DNA vaccine
8. For which age group is the Dengvaxia vaccine recommended?
a) 6 months to 2 years
b) 2 years to 9 years
c) 9 years to 45 years
d) 45 years and above
9. What is the primary concern associated with the Dengvaxia vaccine?
a) It may increase the risk of severe dengue in individuals not previously infected
b) It causes autism
c) It has a low efficacy rate
d) It is expensive
10. Which organization developed the Dengvaxia vaccine?
a) GlaxoSmithKline
b) Merck
c) Sanofi Pasteur
d) Pfizer
11. What is the potential advantage of a tetravalent dengue vaccine over a monovalent vaccine?
a) It provides protection against all four dengue serotypes
b) It is cheaper to manufacture
c) It has fewer side effects
d) It requires fewer doses
12. Which of the following is a potential challenge in developing an effective dengue vaccine?
a) The virus has a low mutation rate
b) The virus has a short incubation period
c) The virus has multiple serotypes
d) The virus is not transmitted by mosquitoes
13. What is the name of the first tetravalent dengue vaccine candidate to reach Phase 3 clinical trials?
a) TAK-003
b) TV003
c) DPIV-Env
d) DENV-1-4
14. Which type of technology is used in the development of TAK-003 dengue vaccine candidate?
a) Recombinant protein technology
b) Virus-like particle technology
c) Live attenuated virus technology
d) Inactivated virus technology
15. What is the potential advantage of a dengue vaccine based on virus-like particles (VLPs)?
a) It does not require a cold chain for storage
b) It provides long-lasting immunity
c) It is safer as it does not contain live virus
d) It is easier to manufacture
16. Which of the following statements about dengue vaccination is true?
a) A single dose of the vaccine provides lifelong protection
b) Multiple doses are required for effective protection
c) Vaccination is recommended for all age groups
d) Vaccination is not recommended for individuals with a history of dengue infection
17. What is the primary aim of the World Health Organization’s (WHO) Global Dengue Strategy?
a) To develop an effective dengue vaccine
b) To reduce the burden of dengue globally
c) To eradicate mosquito vectors
d) To promote public awareness about dengue
18. Which of the following countries was the first to approve the Dengvaxia vaccine for use?
a) Brazil
b) Mexico
c) Philippines
d) India
19. What is the primary challenge in implementing a dengue vaccination program in endemic countries?
a) Lack of political will
b) High cost of the vaccine
c) Logistical challenges in vaccine distribution
d) All of the above
20. Which of the following organizations is leading the development of a novel dengue vaccine candidate called DENV-1-4?
a) National Institutes of Health (NIH)
b) Butantan Institute
c) Walter Reed Army Institute of Research (WRAIR)
d) GlaxoSmithKline
21. What is the primary advantage of a DNA-based dengue vaccine?
a) It can provide long-lasting immunity
b) It is easier to manufacture
c) It is safer than live attenuated vaccines
d) All of the above
22. Which of the following is a potential side effect of the Dengvaxia vaccine?
a) Fever
b) Headache
c) Muscle pain
d) All of the above
23. What is the primary goal of dengue vaccine research?
a) To develop a single-dose vaccine
b) To develop a tetravalent vaccine
c) To develop a vaccine that provides long-lasting immunity
d) All of the above
24. Which of the following organizations is involved in the development of a dengue vaccine candidate called TV003?
a) Merck
b) Sanofi Pasteur
c) Takeda
d) GlaxoSmithKline
25. What is the primary challenge in developing a single-dose dengue vaccine?
a) The need for multiple doses to achieve adequate immunity
b) The lack of funding for research
c) The lack of animal models for testing
d) The high cost of manufacturing
26. Which of the following statements about dengue vaccines is true?
a) All approved dengue vaccines are live attenuated vaccines
b) There are no approved dengue vaccines for use in children under 9 years of age
c) Dengue vaccines provide lifelong protection against all serotypes
d) None of the above
27. What is the primary goal of the WHO’s Dengue Vaccine Initiative?
a) To promote public awareness about dengue
b) To develop new mosquito control strategies
c) To accelerate the development and introduction of dengue vaccines
d) To provide funding for dengue research
28. Which of the following is a potential advantage of a live attenuated dengue vaccine?
a) It provides long-lasting immunity
b) It can be administered orally
c) It is less expensive to manufacture
d) It has fewer side effects
29. What is the primary challenge in developing a dengue vaccine that provides long-lasting immunity?
a) The high mutation rate of the virus
b) The lack of suitable animal models
c) The need for multiple doses
d) The lack of funding for research
30. Which of the following statements about dengue vaccine development is true?
a) A single vaccine candidate has shown promising results in all clinical trials
b) Multiple vaccine candidates are in various stages of development
c) No new dengue vaccine candidates are currently being developed
d) All approved dengue vaccines provide lifelong immunity
Answers:
1. b
2. c
3. b
4. d
5. a
6. a
7. b
8. c
9. a
10. c
11. a
12. c
13. a
14. b
15. c
16. b
17. b
18. c
19. d
20. c
21. d
22. d
23. d
24. c
25. a
26. d
27. c
28. a
29. c
30. b